| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Biologics and the lung: TSLP and other epithelial cell-derived cytokines in asthma
|
Mitchell, Patrick D.
|
|
2017
|
169 |
C |
p. 104-112
9 p.
|
artikel
|
| 2 |
Clinical potential of oligonucleotide-based therapeutics in the respiratory system
|
Moschos, Sterghios A.
|
|
2017
|
169 |
C |
p. 83-103
21 p.
|
artikel
|
| 3 |
Development of therapeutic antibodies to G protein-coupled receptors and ion channels: Opportunities, challenges and their therapeutic potential in respiratory diseases
|
Douthwaite, Julie A.
|
|
2017
|
169 |
C |
p. 113-123
11 p.
|
artikel
|
| 4 |
From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease
|
Dawson, Sarah
|
|
2017
|
169 |
C |
p. 78-82
5 p.
|
artikel
|
| 5 |
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
|
Clarke, Deborah L.
|
|
2017
|
169 |
C |
p. 35-46
12 p.
|
artikel
|
| 6 |
Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation
|
Nixon, John
|
|
2017
|
169 |
C |
p. 57-77
21 p.
|
artikel
|
| 7 |
Nanobodies® † † Nanobody is a registered trademark of Ablynx NV. as inhaled biotherapeutics for lung diseases
|
Van Heeke, Gino
|
|
2017
|
169 |
C |
p. 47-56
10 p.
|
artikel
|
| 8 |
Patient stratification and the unmet need in asthma
|
Swedin, Linda
|
|
2017
|
169 |
C |
p. 13-34
22 p.
|
artikel
|
| 9 |
Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF
|
Murray, Lynne A
|
|
2017
|
169 |
C |
p. 1-12
12 p.
|
artikel
|
Tijdschrift beschrijving